SCHEMBL203111

SCHEMBL203111

CC(C)(C)[Si](C)(C)Oc1[c]cccc1

nearest known ligand 0.33

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.32
CA1 P00915 4/20 0.32
CA9 Q16790 4/20 0.32
ALOX5AP P20292 2/20 0.31
FEN1 P39748 2/20 0.31
PREP P48147 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL872925 0.79
SCHEMBL7723079 0.76 DUT (0.36) CA12CA1CA9
SCHEMBL7716164 0.75 DUT (0.38)
SCHEMBL4456227 0.74 CA12 (0.33) CA12CA1CA9
SCHEMBL29167690 0.73 ALOX5AP (0.37) CA12CA1CA9ALOX5APFEN1
SCHEMBL4438037 0.73 ALDH1A1 (0.44) CA12CA1CA9ALOX5APFEN1
SCHEMBL29026302 0.72 CA12 (0.31) CA12CA1CA9ALOX5APFEN1
SCHEMBL29026260 0.72 LTA4H (0.38) CA12CA1CA9
SCHEMBL14639048 0.72 CA12 (0.35) CA12CA1CA9PREP
SCHEMBL49983 0.71 KIF11 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1817292-B1 NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2015-04-08 EP claimed
US-8088811-B2 Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) JANSSEN PHARMACEUTICA N.V. (BE) 2012-01-03 US claimed
US-20100267670-A1 NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) ZHANG XUQING 2010-10-21 US claimed
US-7781473-B2 Heterocycle derivatives useful as selective androgen receptor modulators (SARMS) J & J Pharmaceutical Research & Development, LLC. (US) 2010-08-24 US claimed
US-7465809-B2 Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) JANSSEN PHARMACEUTICA N.V. (BG) 2008-12-16 US claimed
US-7378416-B2 MIF-inhibitors NOVARTIS AG (CH) 2008-05-27 US claimed
US-20070219189-A1 MIF-INHIBITORS NOVARTIS AG (CH) 2007-09-20 US claimed
EP-1817292-A2 NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-15 EP claimed
US-20060211756-A1 Novel heterocycle derivatives useful as selective androgen receptor modulators (SARMs) JANSSEN PHARMACEUTICA N.V. (BE) 2006-09-21 US claimed
WO-2006055184-A2 NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-26 WO claimed
US-6509426-B2 Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability JAPAN POLYCHEM CORPORATION (JP) 2003-01-21 US claimed
US-6391916-B1 ANTITUMOR AGENTS THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2002-05-21 US claimed
CN-114945619-A Polycarbonate resin, polycarbonate resin composition, optical molded article containing same, and cyclic carbonate 旭化成株式会社 2022-08-26 CN disclosed
EP-1817292-B1 NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2015-04-08 EP disclosed
US-8778988-B2 Endoperoxides and methods of photocatalytically synthesizing endoperoxides WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2014-07-15 US disclosed
US-20120302523-A1 ENDOPEROXIDES AND METHODS OF PHOTOCATALYTICALLY SYNTHESIZING ENDOPEROXIDES WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2012-11-29 US disclosed
US-5856561-A Bisphenol carboxylic acid tertiary ester derivatives and chemically amplified positive resist compositions SHIN-ETSU CHEMICAL CO., LTD. (JP) 1999-01-05 US disclosed
US-5514711-A ANTICARCINOGENIC AGENTS; SIDE EFFECT REDUCTION MITSUBISHI CHEMICAL CORPORATION (JP) 1996-05-07 US disclosed
WO-1994026927-A1 NOVEL N-ALKYLACRIDAN CARBOXYL DERIVATIVES USEFUL FOR CHEMILUMINESCENT DETECTION LUMIGEN, INC. (US) 1994-11-24 WO disclosed
EP-0206765-B1 PROCESS FOR PREPARATION OF ROOPEROL, HYPOXOSIDE AND DERIVATIVES THEREOF ROOPEROL (NA) NV (NL) 1991-03-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211756-A1 Novel heterocycle derivatives useful as selective androgen receptor modulators (SARMs) AR, NR5A1, NR5A2 CA12 4544/4885CA1 4793/4885CA9 4232/4885
US-20070219189-A1 MIF-INHIBITORS MIF, FOXM1, CCR8 CA12 921/4885CA1 1176/4885CA9 1041/4885
US-20120302523-A1 ENDOPEROXIDES AND METHODS OF PHOTOCATALYTICALLY SYNTHESIZING ENDOPEROXIDES QSOX1, GPX4, PRDX2 CA12 1418/4885CA1 562/4885CA9 1429/4885
US-20100267670-A1 NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AR, NR5A1, NR5A2 CA12 4544/4885CA1 4793/4885CA9 4232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.